News

News

Welcome to the homepage of AIHTA!

AIHTA is an acadmic non-profit institute. At our website we wish to present our research and give support for health care decision-making. Here all of our reports are available for free. For further information please contact the AIHTA team.

In the News section you will find our most recent publications: newsletter, project-reports etc. Previous reports you might find via Research areas, Research projects and Repository.

Subscribe to newsletter

Note: this content is only available in German.

Inhalt

Zur Druckversion...

Adobestock-603904097-von-tinashe-npeopleimages-com

©stock.adobe.com

Announcement

Economic Dimensions of Community Nursing: A Systematic Literature Review

Community Nursing is a new model of care in Austria to strengthen the health of the elderly population. The literature review examines the cost-effectiveness of the concept and methods for presenting it. The results are inconclusive. The use of community nursing tends not to be cost-effective in the eleven identified studies, but methodological limitations may have biased the results. The studies are also older and largely not from Europe. Further research using more recent methodological findings from research on complex interventions and evaluation of public health interventions is needed.

Publication: HTA Project Report No. 153: https://eprints.aihta.at/1470/
Contact: Ingrid Zechmeister-Koss

More...

©stock.adobe.com

Announcement

Horizon Scanning in Oncology - Fact Sheets

We are pleased to introduce you eight new Fact Sheets.

Fact Sheet No. 138 (August 2023)
Crisantaspase (Enrylaze®) for the treatment of acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma (LBL)

Fact Sheet No. 139 (August 2023)
Cedazuridine/decitabine (Inaqovi®) for the treatment of newly diagnosed acute myeloid leukaemia (AML)

Fact Sheet No. 140 (August 2023)
Elacestrant (Orserdu®) monotherapy for the treatment of oestrogen receptor (ER)?positive, HER2-negative, locally advanced or metastatic breast cancer

Fact Sheet No. 141 (August 2023)
Talquetamab (Talvey®) for the treatment of adult patients with relapsed and refractory multiple myeloma (MM)

Fact Sheet No. 142 (August 2023)
Epcoritamab (Tepkinly®) as monotherapy for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

Fact Sheet No. 143 (August 2023)
Tislelizumab (Tevimbra®) as monotherapy for the treatment of unresectable, locally advanced, or metastatic oesophageal squamous cell carcinoma (OSCC)

Fact Sheet No. 144 (August 2023)
Nivolumab (Opdivo®) as monotherapy for the adjuvant treatment of Stage IIB or IIC melanoma, or melanoma with involvement of lymph nodes or metastatic disease

Fact Sheet No. 145 (August 2023)
Pembrolizumab (Keytruda®) with trastuzumab, fluoropyrimidine and platinum-containing chemotherapy for the first-line treatment of locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction (GEJ) adenocarcinoma

More...

©stock.adobe.com

Announcement

Robot-assisted surgery in thoracic and visceral indications – Update 2023

Robotic-assisted surgery represents a technically advanced form of a minimally invasive procedure that claims to improve clinical outcomes as well as healthcare resource utilization. This report is an update of a systematic review from 2019, which examined the effectiveness and safety of robotic-assisted surgery in thoracic and visceral indications, compared to open surgery and conventional laparoscopy. In total, 14 indications were investigated, with no evidence identified for five indications. Due to the heterogeneous results and lack of evidence for some study endpoints, a general statement on the effectiveness and safety of robotic-assisted surgery is not possible.

Publication: HTA Project Report No. 108: https://eprints.aihta.at/1461
Contact : Nicole Grössmann-Waniek

More...

©stock.adobe.com

Announcement

Horizon Scanning in Oncology - Fact Sheets

We are pleased to introduce you three new Fact Sheets.

Fact Sheet No. 135 (July 2023)
Tremelimumab (Imjudo®) with durvalumab (Imfinzi®) and platinum-based chemotherapy for the first-line treatment of metastatic non-small cell lung cancer (NSCLC)

Fact Sheet No. 136 (July 2023)
Trifluridine / tipiracil (Lonsurf®, TAS-02) with bevacizumab for the treatment of metastatic colorectal cancer (CRC)

Fact Sheet No. 137 (July 2023)
Sacituzumab govitecan (Trodelvy®) for the treatment of unresectable or metastatic hormone receptor-positive, HER2-negative breast cancer

More...

Note: this content is only available in German.

Inhalt

Zur Druckversion...

©stock.adobe.com

Announcement

Evaluation of individual medical procedures - Reports 2023

We are pleased to introduce our new reports.

Decision Support Documents 2023:

DSD 135: Percutaneous aspiration thrombectomy for pulmonary embolism https://eprints.aihta.at/1454/
DSD 136: Transcranial magnetic resonance-guided high-intensity focused ultrasound treatment in patients with drug-resistant essential tremor https://eprints.aihta.at/1455/
DSD 137: Bleomycin Electrosclerotherapy for Vascular Anomalies: Systematic Review https://eprints.aihta.at/1456/
DSD 138: Electrical auricular vagus nerve stimulation for pain https://eprints.aihta.at/1457/

+ 3 Updates

DSD 41: Percutaneous mitral valve repair with a clip device in patients with mitral regurgitation. 2nd Update 2023 https://eprints.aihta.at/1451/
DSD 111: Allogeneic mesenchymal stem cells for Crohn's Disease-associated complex perianal fistulas. 1st Update 2023 https://eprints.aihta.at/1452/
DSD 118: 177Lu-PSMA Radioligand Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: Systematic Review. 1st Update 2023 https://eprints.aihta.at/1453/

More...